Main Conference Day 2 - Europe/Amsterdam
Main Conference Day 2 - Europe/Amsterdam
07:00 - 07:3030 mins
Morning Spotlight Presentation
Registration and Coffee
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairperson’s Remarks: Oligonucleotide Chemistry and Discovery to Clinic
- Troels Koch, PhD - Chief Technology Officer, Cora Biosciences
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairperson’s Remarks: Regulatory CMC Strategies for Oligonucleotides
- Daniel Waschke, PhD - Associate Regulatory Program Director, F. Hoffmann-La Roche Ltd.
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: Innovations in Peptide Discovery
- David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chemistry of Antisense Oligonucleotides for the Correction of Unproductive Splicing
- Peter Hagedorn - Senior Director, Head of Bioinformatics, Contera Pharma
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides
- Chris Chorley - Regulatory Program Director, Roche
08:05 - 08:3530 mins
Peptide Discovery to CMC
KnotBody Technology: Presentation of Cys-rich “Knottin” Peptides within Antibody Scaffolds Unleashes the Power of Phage Display Technology
- John McCafferty, PhD - Chief Technology Officer, Maxion Therapeutics
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Design and Chemical Optimization of Activating Oligonucleotides for Therapeutic HbF Induction in Sickle Cell Disease
- Robert Place - Chief Technology Officer, MiNA Therapeutics Limited
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Regulatory CMC Strategies and Health Authority Interactions for Oligonucleotide Programs
- Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
08:35 - 09:0530 mins
Peptide Discovery to CMC
Identification of Cyclic Peptides Synthetically Lethal to MTAP Deletion Cancer Cells through High Throughput Phenotypic Screening
- Monika Papayova - EPSRC Doctoral Prize Research Fellow, University of Southampton
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA
- Pachamuthu Kandasamy, PhD - Vice President, Medicinal Chemistry, Wave Life Sciences
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Regulatory Landscape for Synthetic Peptides and Oligonucleotides: EMA Insights and Guideline Updates
- Eleonora Marino - Pharmaceutical Quality Specialist, European Medicines Agency
09:05 - 09:3530 mins
Peptide Discovery to CMC
Targeting Fibrotic Tissue for Peptide-based Diagnostic and Therapeutic Applications
- Brenno Masina - Senior Graduate Student, ETH Zurich
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break
09:45 - 09:5510 mins
TIDES Talks in Poster and Exhibit Hall
Sustainable Scale in RNAi Manufacturing
- David Entwistle, Ph.D. - Senior Director, Technical Client Services, Codexis
09:55 - 10:005 mins
TIDES Talks in Poster and Exhibit Hall
TIDES Talk
10:15 - 10:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited
- Lucas Bethge, Ph.D. - VP, Group Leader Chemistry, Silence Therapeutics
10:15 - 10:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Finding the Right Balance: How Formulation Aspects and Regulatory Expectations Affect Steam Sterilization of Antisense Oligonucleotide (ASO) Drug Products
- Bhavani Prasad Vinjamuri, Ph.D - Scientist II, Biogen
10:15 - 10:4530 mins
Peptide Discovery to CMC
Posttranslational Modifications in Peptide Design and Activity
- Anne Conibear, BSc(Hons) MSc PhD - Assistant Professor, Peptide and Protein Chemistry, Technische Universität Wien
10:45 - 11:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
AIR-001: A Highly Potent and Precise GalNAc-conjugated RNA Base Editing Treatment for Alpha-1 Antitrypsin Deficiency
- Sriram Sathy, Ph.D. - Chief Scientific Officer, AIRNA
10:45 - 11:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Late Breaking Presentation
10:45 - 11:1530 mins
Peptide Discovery to CMC
Cyclisation of the Analgesic α-conotoxin Vc1.1 with a Non-natural Linker to Improve Biopharmaceutical Properties
- David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
11:15 - 11:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
AIC468, A First-in-class Antisense Oligonucleotide Targeting BKV in Kidney Transplant Patients
- Jacques Dumas - Chief Scientific Officer, Arrakis Therapeutics
11:15 - 11:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Panel Discussion with Session Speakers
11:15 - 11:4530 mins
Peptide Discovery to CMC
Late Breaking Presentation
11:45 - 11:505 mins
Oligonucleotide Discovery, Preclinical and Clinical
Transition to Spotlight Presentations
11:45 - 11:505 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Transition to Spotlight Presentations
11:45 - 11:505 mins
Peptide Discovery to CMC
Transition to Spotlight Presentations
Spotlight Presentations
11:50 - 12:2030 mins
Spotlight Presentation 1
Digital Manufacturing in Practice: Enabling Efficient and Compliant Large-scale Production
- Ralph Koitz - Head of Digital Manufacturing & Data Analytics, Bachem
11:50 - 12:2030 mins
Spotlight Presentation 2
Operational Optimization for Oligonucleotides - Maximizing Synthesizer Performance, Reliability, and Longevity
11:50 - 12:2030 mins
Spotlight Presentation 3
Integrated Analytical Workflows for Synthetic Peptide Development: From Peptide Separation to Sequence Confirmation
- Holger Stalz, PhD - LCMS Product Specialist, Agilent Technologies
12:20 - 13:2565 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Luncheon in Poster and Exhibit Hall
12:40 - 13:0020 mins
TIDES Talks in Poster and Exhibit Hall
Advancing Beyond Injections: Technologies Driving Oral Delivery of Peptides
- Karunakar (Karu) Sukuru, R.Ph., Ph.D - Global Vice President, Pharma Product Development and Head, Scientific Advisory, Catalent
13:25 - 13:5530 mins
Spotlight Presentation 1
OCELOT®: The Open, Unified Software Platform for Modern Oligo Manufacturing
- Stefan Hyde - Automation Manager, Asahi Kasei Bioprocess America
13:55 - 14:005 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairman’s Remarks: Emerging RNA and OIigonucleotide Modalities
13:55 - 14:005 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairman’s Remarks: Emerging Technologies in Oligonucleotide Manufacturing
13:55 - 14:005 mins
Peptide Discovery to CMC
Chairman's Remarks - Peptide Process Development and Manufacturing
14:00 - 14:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
smartRNA: A First-in-Class Scalable RNA Therapeutics Platform for Protein Upregulation
- Anja Hoeg - Entrepreneur, Smartrna
14:00 - 14:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Enzymatic Ligation for the Production of Oligonucleotides
- Nicolo Zuin Fantoni, PhD - Senior Scientist, Oligonucleotides, F. Hoffmann-La Roche Ltd.
14:00 - 14:3030 mins
Peptide Discovery to CMC
Case Studies of Pre-clinical Development and IND Acceleration for Peptides
- Victoire Laude - Innovation Scientist, PolyPeptide Laboratories
14:30 - 15:0030 mins
Oligonucleotide Discovery, Preclinical and Clinical
Next-generation mRNA Vaccines and Therapeutics
- Ashish Sarode, PhD - Director, Delivery & Formulations, mRNA Center of Excellence, Sanofi
14:30 - 15:0030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Stirring Things Up: Integrating Stirred-Bed SPOS and Enzymatic Ligation for Industrial Oligonucleotide Production
14:30 - 15:0030 mins
Peptide Discovery to CMC
Accelerate Timeline to Start PhI: Phase Appropriate Development and Integrated Drug Product Supply
- Tobias Kapp, PhD - Global Head of Peptide Development, CordenPharma
15:00 - 15:3030 mins
Oligonucleotide Discovery, Preclinical and Clinical
EMA Perspectives on mRNA Vaccines and Therapeutics
- Brian Dooley - Pharmaceutical Quality Senior Specialist, European Medicines Agency
15:00 - 15:3030 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Advancing siRNA Manufacturing with User-defined Phosphorothioate Stereochemistry
- Stefan Lutz, PhD - Chief Scientific Officer, Codexis
15:00 - 15:3030 mins
Peptide Discovery to CMC
A Mild and Sustainable Platform for Disulfide Bond Formation in Peptide Manufacturing Using Dehydroascorbic Acid
- Alexander Kleinsmann, PhD - Director R&D, CMC Development, Bachem AG
15:30 - 16:1545 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break
15:40 - 15:5010 mins
TIDES Talks in Poster and Exhibit Hall
From Building Blocks to Therapeutics: Thermo Fisher’s Integrated RNA & Oligonucleotide Supply Chain
- Christoph Schmoelzer - Head of Product Management, Advanced Therapies, Thermo Fisher Scientific
16:15 - 16:4530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Precision RNA Splicing through Targeted Pseudo-exon Activation: A Novel Platform Unlocking Broad Therapeutic Potential
- Poul Sorensen - CEO, Inverna therapeutics
16:15 - 16:4530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Oligonucleotide Analytical and Process Development
16:15 - 16:4530 mins
Peptide Discovery to CMC
Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development
- Federico Di Chiaro - Senior CMC Project Manager, Zealand Pharma
16:45 - 17:1530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Novel Circular RNA Therapeutics for Infectious and Non-infectious Diseases
- Judit Tomsen Melero, PhD - Preclinical Project Manager, noctuRNA Therapeutics
16:45 - 17:1530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Oligonucleotide CMC Application
16:45 - 17:1530 mins
Peptide Discovery to CMC
Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure
- Stephanie Coffin - Global Peptide Drug Substance Steward, Eli Lilly
17:15 - 19:00105 mins
Networking Reception
Evening Networking Reception
* 活动内容有可能不事先告知作更动及调整。